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Background: The Vav family of Rho/Rac guanosine nucleotide exchange factors comprises three members in
mammalian cells. Vav3 enhances androgen receptor (AR) activity during progression to androgen independence in
prostate cancer. We examined Vav3 small interfering RNA (siRNA) effects on cell proliferation and apoptosis in
docetaxel-treated LNCaP cells under chronic hypoxia (LNCaPH).
Methods: We examined individual and combined effects of Vav3 siRNA (si-Vav3) and docetaxel on cell growth
and apoptosis under chronic hypoxia by cell proliferation, flow cytometric, DNA fragmentation, and immunoblot
analyses. To clarify the molecular basis of si-Vav3- and docetaxel-induced apoptosis, we analyzed alterations in
phosphatidylinositol 3-kinase (PI3K)/Akt, extracellular signal-regulate kinase (ERK), c-jun N-terminal kinase (JNK),
and AR pathways using kinase inhibitors in LNCaPH cells. The effects of si-Vav3/atelocollagen complex alone or in
combination with docetaxel were assessed on xenografts in nude mice by tumor growth delay.
Results: Vav3 overexpression was observed in LNCaPH compared with the expression under normoxia. Interrupting
Vav3 signaling using siRNA enhanced docetaxel-induced cell growth suppression compared with that induced by
docetaxel alone by inhibition of Akt and ERK phosphorylation, resulting in AR phosphorylation inhibition. In
addition to increased B-cell lymphoma 2 (Bcl-2) phosphorylation through JNK signaling in response to docetaxel,
si-Vav3 enhanced docetaxel-induced apoptosis, as characterized by the accumulation of sub-G1 phase cells and
DNA fragmentation, through Bcl-xL/Bcl-2-associated death promoter (Bad) dephosphorylation, resulting in increased
caspase-9, caspase-3, and cleaved poly(ADP-ribose) polymerase activation. Xenograft tumor growth was slightly
inhibited by si-Vav3/atelocollagen complex injection and combined use of si-Vav3/atelocollagen complex and
docetaxel produced a greater effect than docetaxel alone.
Conclusions: Interrupting Vav3 signaling enhances docetaxel-induced apoptosis in LNCaP cells under chronic
hypoxia by inhibiting the PI3K/Akt, ERK, and AR signaling pathways. Therapy targeting Vav3 in combination with
docetaxel may have practical implications for managing castration-resistant prostate cancer.
Keywords: Vav3, Docetaxel, Androgen receptor, Prostate cancer, Chronic hypoxia* Correspondence: TAKE@oita-u.ac.jp
1Department of Urology, Oita University Faculty of Medicine, 1-1 Idaigaoka,
Hasama-machi, Yufu, Oita 879-5593, Japan
Full list of author information is available at the end of the article
© 2013 Nomura et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Nomura et al. Molecular Cancer 2013, 12:27 Page 2 of 15
http://www.molecular-cancer.com/content/12/1/27Background
Prostate cancer is the most frequently diagnosed cancer in
the world. Most prostate cancers are initially dependent
on androgens for growth, and patients with prostate can-
cer receive hormonal therapy. Androgen deprivation by
medical or surgical castration contributes significantly to
disease control during early stages of prostate cancer;
however, the effect is usually palliative, and a majority of
prostate cancers eventually progress to a hormone-refrac-
tory phenotype against which current treatments are rela-
tively ineffective [1]. The progression of prostate cancer
from the androgen-dependent to androgen-independent
state is the main obstacle in improving the survival and
quality of life in patients with advanced prostate cancer.
Therefore, much attention has been focused on the evolu-
tion from androgen-dependent to androgen-independent
prostate cancer, and the establishment of novel thera-
peutic strategies against hormone-refractory prostate can-
cer (HRPC) is desirable.
In the past, molecular mechanisms for the progression
to the hormone-refractory state have been proposed based
on experimental evidence. The androgen receptor (AR)-
dependent mechanisms include (a) androgen-independent
activation of AR [2,3], (b) AR overexpression or muta-
tions, which could allow AR to respond to lower levels of
androgens [4] or be directly activated by other ligands [5],
(c) increased expression of steroidogenic enzymes [6], and
(d) indirect activation of AR by cell-surface receptors such
as HER2 [7], the interleukin-6 receptor [8] and G-protein-
coupled receptors [9]. The AR-independent mechanisms
include (e) mutations of tumor suppressor genes [10], (f)
expression of various oncogenes affecting cell growth and
death [11], (g) enhanced angiogenesis [12], (h) bypassing
the AR pathway [13], and (i) prostate cancer stem cell
regeneration [14].
Recently, Lyons et al. reported a novel ligand-independent
AR activation through Rho guanosine triphosphatase
(GTPase) signaling in prostate cancer in vivo and in vitro
[15]. The levels of Vav3, a Rho GTPase guanine nucleotide
exchange factor (GEF), are elevated in human prostate
cancer specimens, and they increase during the progression
of prostate cancer to androgen independence by enhance-
ment of AR transcriptional activity [16,17]. The Vav gene
(Vav1) was first identified in hematopoietic cells with
oncogenic activity. Since the discovery of the Vav oncogene,
new family members have been identified in mammalian
cells (Vav2 and Vav3) [18-20]. The biochemical functions of
Vav family proteins have been extensively investigated. Vav1
expression is restricted to hematopoietic cells, and it is
involved in the formation of the immune synapse. Vav2 and
Vav3 are more ubiquitously expressed [20]. Vav proteins
contain the Dbl homology domain, which confers GEF
activity, as well as protein interaction domains that allow
them to function in pathways regulating actin cytoskeletonorganization [21]. In particular, their GEF activity is the
most important function among them. Vav3, a signal
transducer of receptor protein tyrosine kinase, is
involved in various cellular signaling processes including
cell morphology modulation and cell transformation with
oncogenic activity [22]. In the current study, Vav3 was
demonstrated to bind to phosphatidylinositol 3-kinase
(PI3K), leading to PI3K activation with cell transformation
activity [23].
In a previous report, Dong et al. found that Vav3 en-
hances AR activity partially through PI3K/Akt signaling
and stimulates androgen-independent growth in prostate
cancer [17]. We further revealed that tumor cell hypoxia
induced Vav3 overexpression with androgen-independ-
ent growth and malignant behavior in LNCaP cells
[24,25]. Therefore, we hypothesized that Vav3 has an im-
portant role in regulating the growth and survival of
prostate cancer cells under hypoxic conditions and that
it is a novel therapeutic target for the treatment of
HRPC. In recent years, taxane-based chemotherapy has
contributed to improvements in treatment outcomes in
prostate cancer, and docetaxel has become a standard
chemotherapeutic agent for treating HRPC; however,
docetaxel does not exhibit sufficient activity when ad-
ministered as a single agent [26-28]. However, when
docetaxel is used in combination with other therapeutic
modalities, this therapeutic strategy may provide mean-
ingful improvements in the management of HRPC. In
this study, we report studies assessing in vitro and
in vivo combinations of docetaxel with small interfering
RNA (siRNA) for Vav3.
To the best of our knowledge, we have reported for the
first time that interrupting the Vav3 signaling pathway
using siRNA induces apoptosis and enhances docetaxel
sensitivity through the inhibition of PI3K/Akt, extracellu-
lar signal-regulate kinase (ERK), and AR signaling axis in
human prostate cancer.
Results
Expression levels of Vav3 in parental and chronic hypoxic
LNCaP cells
The expression of Vav3 was assessed by immunoblot ana-
lysis and immunocytochemistry in parental LNCaP cells
(LNCaP) and LNCaP cells cultured under hypoxic condi-
tions for over six months (LNCaPH). Compared with
LNCaP cells, LNCaPH cells and KPK13 cells as positive
control expressed higher levels of Vav3 (Figure 1A and B).
Effects of si-Vav3 and docetaxel on Vav3 expression and
cell proliferation in LNCaPH cells
Because Vav3 increased LNCaP cell growth in vitro and
Vav3 overexpression was observed in LNCaPH cells
exhibiting androgen-independent behavior compared















Figure 1 Expression of Vav3 in LNCaP, LNCaPH, and KPK13 cells.
A, immunoblot analysis of cell lysates derived from LNCaP, LNCaPH,
and KPK13 cells. M. W., Molecular weight. B, immunocytochemical
staining of Vav3 in LNCaP, LNCaPH, and KPK13 cells.
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be a therapeutic target for the treatment of HRPC.
LNCaPH cells were transiently transfected with either si-
Vav3 or si-Scr. After 72 h, cells were harvested and
subjected to immunoblot analysis, revealing that si-Vav3
effectively downregulated the expression of Vav3 com-
pared with its control expression (Figure 2A). Conversely,
Vav3 expression was unaffected by docetaxel treatment.
To determine the docetaxel sensitivity of si-Vav3-treated
cells, cells transfected with si-Vav3 or si-Scr were treated
with 5 nM docetaxel for 72 h and assayed for cell prolifer-
ation and live/death analyses. Treatment with docetaxel or
si-Vav3 inhibited cell growth in a time-dependent manner,
and when LNCaPH cells were treated with si-Vav3 in the
presence of docetaxel, sensitivity to docetaxel was signifi-
cantly enhanced (P < 0.05) (Figure 2B). We further con-
firmed this enhanced cell growth inhibition with the
results of the cell live/death assay. The assay stains live
cells with a green fluorescence dye and dead cells with a
red fluorescence dye. We observed that control si-Scr andsi-Vav3 treatment resulted in the death of 0.5% and 8% of
cells respectively, whereas treatment with docetaxel
alone or si-Vav3 plus docetaxel resulted in the death of
48% and 78% of cells per field, respectively (Figure 2C).
These results suggest that Vav3 depletion significantly
sensitizes LNCaPH cells to docetaxel treatment by indu-
cing cell death.
Effects of si-Vav3 and docetaxel on the activation of Akt,
ERK, and JNK signaling in LNCaPH cells
To clarify the molecular mechanisms by which si-Vav3
and docetaxel promote the death of LNCaPH cells, we
investigated the effects of si-Vav3 and docetaxel on the
phosphorylation of Akt, ERK, and JNK. LNCaPH cells
were treated with si-Vav3, 5 nM docetaxel, or si-Vav3 plus
5 nM docetaxel for 48 h. Treatment with si-Vav3 led to
the attenuation of Akt phosphorylation at Ser 473, a site
required for Akt activation, and ERK phosphorylation at
Thr 202 and Tyr 204, which are sites required for ERK
activation, but no effect was observed on JNK phosphoryl-
ation (Figure 2D). Similarly, docetaxel treatment attenu-
ated Akt and ERK phosphorylation and strongly induced
JNK phosphorylation at Thr 183 and Tyr 185, which are
sites required for JNK activation (Figure 2D). When
LNCaPH cells were treated with si-Vav3 plus docetaxel,
Akt phosphorylation was completely abolished with
the inhibition of ERK phosphorylation and JNK acti-
vation (Figure 2D). Figure 2E summarizes the results of
three independent experiments. These results suggest that
LNCaPH cells display Akt and ERK activation and that
si-Vav3 negatively regulates PI3K/Akt and ERK pathway
activation, enhancing the effects of docetaxel.
Effects of si-Vav3 and docetaxel on the apoptotic cell
death of LNCaPH cells
To investigate whether the growth-inhibitory effects of the
combination of si-Vav3 and docetaxel may be triggered by
increased apoptosis in LNCaPH cells, we evaluated the
apoptotic cells by flow cytometry, which assessed a sub-
G1 population of apoptotic cells, and enzyme-linked im-
munosorbent assay (ELISA) using Cell Death Detection
ELISAPLUS. Treatment with 5 nM docetaxel led to in-
creased apoptosis in LNCaPH cells in a time-dependent
manner, but the sub-G1 population was slightly increased
by si-Vav3 alone. When LNCaPH cells were treated with
si-Vav3 plus docetaxel, a strong induction of apoptosis
was observed (Figure 3A). Similarly, the addition of si-
Vav3 to docetaxel markedly induced apoptosis in a
docetaxel concentration-dependent manner (Figure 3B).
Among cells treated with si-Vav3 plus 5 nM docetaxel for
72 h, 42.4, 9.0, 10.8, and 37.8% of cells were in the sub-G1,
G1, S, and G2/M fractions, respectively (Figure 3C). In
LNCaPH cells treated with si-Vav3 or 5 nM docetaxel for




































































Figure 2 Effects of Vav3 siRNA (si-Vav3) and docetaxel (DTX) on cell proliferation and Akt, ERK, and JNK activation in LNCaPH cells.
A, Vav3 siRNA (si-Vav3) and control scramble siRNA (si-Scr) were added to the medium using a lipophilic transfection-enhancing reagent
(Lipofectamine RNAiMAX) in the presence or absence of DTX. Cells were harvested after 72 h, and immunoblot analysis was performed using
anti-Vav3 antibody. Blots were stripped and reprobed with an antibody against β-tubulin. B, effects of si-Vav3 in the presence or absence of DTX
on the proliferation of LNCaPH cells were determined by cell counting. Values represent the mean ± SE of three independent experiments.
Asterisk indicates P <0.05 compared with LNCaPH cells treated with DTX alone. C, live/death viability/cytotoxicity kit assay was used to detect live
(green) and dead (red) cells using fluorescence microscopy (4× magnification). D, phosphorylation of Akt, ERK, and JNK induced by si-Vav3 in the
presence or absence of DTX was determined by immunoblot analysis using phospho-Akt (Ser 473), phospho-ERK (Thr 202/Tyr 204), and phospho-
JNK (Thr 183/Tyr185) antibodies. Blots were stripped and reprobed with antibodies against total Akt, total ERK, total JNK, and β-tubulin.
E, phosphorylation levels of Akt, ERK, and JNK in LNCaPH cells were scored as 1.00, and each value is shown as a fold stimulation. Values
represent the mean of three independent experiments. Asterisk indicates P < 0.05 compared with LNCaPH.
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resulted in a 40.2-fold increase in DNA fragmentation
compared with the untreated control (Figure 3D). These
results are consistent with the significant growth inhib-
ition of LNCaPH cells induced by si-Vav3 plus docetaxel,
and these combined effects were associated with a large
increase in the number of apoptotic cells.
Because apoptosis can be triggered by death receptor-
mediated or mitochondria-mediated cascades depend-
ing on the type of caspase activation, we evaluated
caspase-8, caspase-9, and caspase-3 activation and sub-
sequent cleavage of PARP engaged in DNA repair in
LNCaPH cells treated with si-Vav3, 5 nM docetaxel, orsi-Vav3 plus 5 nM docetaxel for 48 h. Immunoblot ana-
lysis revealed that si-Vav3 or docetaxel alone induced
the activation of caspase-9 and caspase-3 and cleavage
of PARP, respectively. When LNCaPH cells were treated
with si-Vav3 plus docetaxel, we observed enhanced
caspase-9 and caspase-3 processing and PARP cleavage
(Figure 3E). In this series of experiments, we did not ob-
serve any activation of caspase-8 (data not shown). To
clarify the extent of caspase and PARP cleavage in
LNCaPH cells, these results were compared with those
in LNCaP cells treated with 10 nM DTX (a known
apoptosis inducer) for 72 h. These results collectively
provide supportive evidence that treatment with si-Vav3
ATime (hours)

























































































































































Figure 3 Effects of Vav3 siRNA (si-Vav3) and docetaxel (DTX) on apoptosis and Bcl-2, Bad, and AR activation in LNCaPH cells.
A, B, C and D, si-Vav3 in the presence or absence of DTX induced apoptosis in LNCaPH cells, as detected and quantified by flow cytometry
and DNA fragmentation. Note the percent of apoptotic cells with sub-G1 DNA content and fold increase in DNA fragmentation. LNCaPH cells
were treated with or without si-Vav3 in the presence or absence of 5 nM DTX for the indicated times (A) or DTX at the concentrations of 0, 1, 2.5,
and 5 nM for 72 h (B). Values represent the mean ± SE of three independent experiments. Asterisk indicates P <0.05 compared with LNCaPH cells
treated with DTX alone. C, change in the cell cycle distribution in response to si-Vav3 in the presence or absence of DTX for 72 h. D, detection of
apoptotic cells using Cell Death Detection ELISAPLUS following 24-h treatment with si-Vav3 in the presence or absence of 5 nM DTX. Values
represent the mean ± SE of three independent experiments. Asterisk indicates P < 0.05 compared with LNCaPH cells treated with DTX alone.
E, caspase-9 and caspase-3 activation and PARP cleavage after treatment with si-Vav3 in the presence or absence of DTX for 72 h. Blots were
stripped and reprobed with an antibody against β-tubulin. LNCaP cells were treated with 10 nM DTX (a known apoptosis inducer) for 72 h as a
positive control for apoptosis. F, Bcl-2, Bad, and AR phosphorylation induced by si-Vav3 in the presence or absence of DTX was determined by
immunoblot analysis using phospho-Bcl-2 (Ser 70), phospho-Bad (Ser 112), and phospho-AR (Ser 81) antibodies. Blots were stripped and reprobed
with antibodies against total Bcl-2, total Bad, total AR, and β-tubulin.
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mitochondrial pathway.
To further elucidate the molecular mechanisms under-
lying si-Vav3- and docetaxel-induced apoptosis of LNCaPH
cells, we investigated the Bcl-2 family proteins and AR,
which are known to be regulated by PI3K/Akt, ERK, or
JNK signaling. We observed that the levels of Bcl-2 phos-
phorylated at Ser 70, but not the total levels of Bcl-2 pro-
tein, were increased by docetaxel compared with in the
level of control (nontreated or si-Scr-transfected) cells,
whereas the levels of Bad phosphorylated at Ser 136 but
not total levels of Bad protein were decreased by treatment
with si-Vav3 and docetaxel. In addition to Bcl-2 family acti-
vation, si-Vav3 decreased the levels of AR phosphorylation
at Ser 81, but molecular events were not affected by
docetaxel (Figure 3F). These results suggest that si-Vav3-
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Figure 4 Effects of specific kinase inhibitors on select signaling pathw
cells were pretreated with 25 μM LY294002, 20 μM U0126, and 10 μM SP60
Control cells were grown in the presence of DMSO. A, note the percent of
± SE of three independent experiments. Asterisk indicates P < 0.05 compar
antibodies that specifically recognize total and phosphorylated Akt, ERK, JN
against β-tubulin.activation of Bcl-2, Bad, and AR through independent
pathways in LNCaPH cells.
AR phosphorylation depends on the activation of PI3K/
Akt and ERK signaling in LNCaPH cells
To determine whether inhibition of selected survival path-
ways is sufficient to induce apoptosis, we used pathway-
specific inhibitors of Akt, ERK, and JNK signaling in par-
ental LNCaP and LNCaPH cells. The effects of LY294002
(PI3K inhibitor), U0126 (mitogen-activated protein kinase
inhibitor), and SP600125 (JNK inhibitor) on apoptosis
were examined by flow cytometry. In these experiments,
serum-starved cells were treated with LY294002 (25 μM)
or U0126 (20 μM) alone or together for 48 h. LY294002 or
U0126 alone increased the percentage of apoptotic cells
compared with the control (DMSO-treated) cells in both
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0125 alone or the combination of LY294002 and U0126 for 48 h.
apoptotic cells with sub-G1 DNA content. Values represent the mean
ed with LNCaP cells. B, immunoblot analysis was performed using
K, and AR. Blots were stripped and reprobed with an antibody
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fects were not additive because the levels of ERK phos-
phorylation were not high compared with those of Akt
phosphorylation in both LNCaP and LNCaPH cells
(Figure 4A and B). LNCaP cells were less sensitive to
LY294002 compared with LNCaPH cells because the
phosphorylation level of Akt was lower in LNCaP cells
than in LNCaPH cells, but the effects of U0126 in LNCaP
and LNCaPH cells were equivalent because the phosphor-
ylation level of ERK was similar in both cell lines. In con-
trast, when cells were treated with SP600125, we observed
no change in the percentage of apoptotic cells in both
LNCaP and LNCaPH cells (Figure 4A).
To further evaluate whether PI3K/Akt, ERK, and JNK
signaling pathways affect AR phosphorylation, we per-
formed immunoblot analysis using pathway-specific in-
hibitors. The AR phosphorylation level was higher in
LNCaPH cells than in LNCaP cells. LY294002 or U0126
alone weakly decreased AR phosphorylation at Ser 81 in
LNCaPH cells, but when these two inhibitors were
added simultaneously, we found that AR phosphoryl-
ation was completely abolished (Figure 4B). In contrast,
AR phosphorylation was strongly inhibited by LY294002
or U0126 alone due to the lower phosphorylation level
of AR in LNCaP cells. The level of phosphorylated AR
was associated with the induction of apoptosis in both
LNCaP and LNCaPH cells (Figure 4A and B). These re-
sults suggest that Vav3 enhances the phosphorylation of
AR at Ser 81 through PI3K/Akt and ERK pathways in
LNCaPH cells. When LNCaP and LNCaPH cells were
treated with SP600125, no alteration in AR phosphoryl-
ation was observed (Figure 4B). This result indicates that
JNK is an independent signaling component and its sig-
naling does not converge with PI3K/Akt and ERK, which
affect the phosphorylation of AR in both LNCaP and
LNCaPH cells.
In vivo antitumor activity of si-Vav3 alone and in
combination with docetaxel
We first assessed the dose–response relationship of si-
Vav3/atelocollagen complex therapy to optimize the ef-
fects of si-Vav3. The effects of si-Vav3 depended on the
amount of the si-Vav3/atelocollagen complex, but the
difference in the effects of si-Vav3 between 2.5 μg and
10 μg of the siRNA/atelocollagen complex was not large
(Figure 5A). Therefore, we selected 2.5 μg of si-Vav3/
50 μl/tumor as the optimal concentration for combin-
ation therapy with docetaxel. In our preliminary studies,
the docetaxel dose of 20 mg/kg maximally suppressed
tumor growth without significant toxicity in mice.
Therefore, we chose 10 mg/kg as a suboptimal dose in
the subsequent studies. The tumor growth curves shown
in Figure 5B demonstrate that the growth-inhibitory ef-
fect of si-Vav3 alone was weak, but the combination ofsi-Vav3 and docetaxel was highly effective in inhibiting
LNCaPH tumor growth. On day 70, the average tumor
volume for control mice treated with saline was 6.9-fold
greater than that measured when treatment was initi-
ated. For mice treated with si-Vav3, the tumor volumes
were 5-fold greater and the size of tumors on day 70
were statistically smaller than those of tumors from mice
treated with the vehicle control (P < 0.01). Docetaxel
significantly inhibited tumor growth, and the tumor vol-
ume on day 70 was slightly larger than the average
tumor volume determined when treatment was initiated.
Tumors from mice treated with si-Vav3 plus docetaxel
were statistically smaller than those from mice treated
with docetaxel alone (P < 0.01), and the tumor volume
on day 70 was 59% smaller than that when treatment
was initiated. It appears reasonable to suppose that a
lower concentration of docetaxel can be used in combin-
ation therapy with si-Vav3 because wide differences were
not observed between these two groups despite the stat-
istical significance of the differences. In addition, during
a 70-day observation period, we did not note any toxicity
in mice treated with si-Vav3 plus docetaxel, as evaluated
by their body weights and physical appearance (data not
shown). These results in tumor xenografts support the
data of the combined effect of si-Vav3 with docetaxel on
cancer cell growth in vitro.
On day 70 after inoculation, tumor tissues were
harvested from euthanized mice and subjected to immu-
noblot analysis of Vav3, H&E staining and immunohisto-
chemical staining of Vav3, Ki-67, pAR, and a commercially
available cell death marker, M30 CytoDeath. Treatment
with si-Vav3 effectively downregulated Vav3 expression
compared with its expression level in control and si-Scr-
treated tumors, illustrating the effectiveness of intra-
tumoral injection (Figure 5C). Histological evaluation
revealed that docetaxel alone or si-Vav3 plus docetaxel
caused necrosis in some areas of xenograft tumors
(Figure 5D). Significant downregulation of Vav3 staining
was observed in tumors from mice treated with si-Vav3
alone or in combination with docetaxel but not in tumors
from mice treated with docetaxel alone (Figure 5D). Repre-
sentative immunohistochemical staining of Ki-67, pAR,
and M30 CytoDeath is shown in Figure 5D, and the immu-
nohistochemical findings are summarized in Figure 5E.
The mean percentage of Ki-67-positive tumor cells in si-
Vav3- or docetaxel-treated tumors was significantly de-
creased compared with that in control tumors (42 ± 8%
and 11 ± 5%, respectively, versus 82 ± 10%, P < 0.005), and
an even more significant reduction was observed in tumors
treated with si-Vav3 plus docetaxel (7 ± 3%, P < 0.005). A
significant decrease in the number of pAR-positive cells
was observed in tumors treated with si-Vav3 alone or in
combination with docetaxel compared with the number of
pAR-positive cells in control tumors (45 ± 9% and 43 ±
AD
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Figure 5 Effects of Vav3 siRNA (si-Vav3) and docetaxel (DTX) on xenograft tumor growth. LNCaPH cells implanted subcutaneously into
nude mice and treated with si-Vav3 and/or DTX. A, dose–response curves of si-Scr and si-Vav3. Changes in the tumor volume were followed over
time. The initial tumor volume (n = 8) was considered as 100%, and the average tumor volumes are expressed as percentages of the average
initial tumor volume of each group on day 21 after LNCaPH cell inoculation. Values represent the mean ± SE. Asterisk indicates P <0.05 compared
with the findings in control tumors. Arrows indicate treatment days. B, in vivo combination study in LNCaPH bearing nude mice. Change in the
tumor volume was followed over time. The initial tumor volume (n = 8) was considered as 100%, and the average tumor volumes are expressed
as percentages of the average initial tumor volume of each group on day 21 after LNCaPH cell inoculation. Values represent the mean ± SE.
Asterisk indicates P <0.05 compared with the findings in control tumors. Arrows indicate treatment days. C, immunoblot analysis of Vav3 in
control, si-Scr-treated, and si-Vav3-treated tumors was performed using an anti-Vav3 antibody. Blots were stripped and reprobed with an antibody
against β-tubulin. D, representative H&E staining (100× magnification) and immunohistochemical analysis of Vav3, Ki-67, pAR, and M30 CytoDeath
in xenograft tumor specimens (200× magnification ). E, data table lists the mean ± SE for four groups.
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mors treated with docetaxel alone (89 ± 8%). The average
apoptotic index for the control tumors was 0.4 ± 0.1%
compared with 8 ± 5% (P < 0.05) and 24 ± 8% (P < 0.005)
in tumors from mice treated with si-Vav3 and docetaxel,
respectively. Tumors from mice treated with the combin-
ation of si-Vav3 and docetaxel exhibited the highest apop-
totic index (35 ± 9%), which was significantly greater than
that in control tumors (P < 0.005). Compared with the re-
sults obtained in tumors from mice treated with docetaxel
alone, the Ki-67 labeling (P < 0.05) and apoptotic indices
(P < 0.05) and the number of pAR-positive cells (P < 0.05)
were all statistically significant in tumors treated with the
combination of si-Vav3 and docetaxel.
Discussion
Docetaxel is a microtubule-targeting drug currently used
as a standard first-line chemotherapeutic agent for the
management of HRPC that has contributed to improved
survival and quality of life in patients with advanced
prostate cancer; however, its effectiveness is limited by
intolerance and the development of docetaxel-refractory
prostate cancer [26-28]. It is therefore reasonable to ex-
pect further improvements in treatment outcomes when
docetaxel is combined with other therapeutic modalities
active against prostate cancer. Because the Vav3 onco-
gene is overexpressed in androgen-independent prostate
cancer, in which it regulates cell growth [16,17], verifying
whether Vav3 is a signaling molecule appears beneficial
for establishing a new therapeutic target for treating
HRPC in combination with docetaxel. We first tested
the anti-cancer potential of interrupting the Vav3 signal-
ing pathway using siRNA followed by investigating the
impact of si-Vav3 in combination with docetaxel. The
goals of this study were to (1) explore Vav3 as a novel
therapeutic target for human prostate cancer, (2) define
the biological effects of si-Vav3 when combined with
docetaxel in human prostate cancer cells in culture and
experimental animal models, and (3) characterize the
downstream signaling pathways of Vav3 in human pros-
tate cancer cells. This approach allowed us to advance
our understanding of the possible importance of Vav3 as
an efficacious therapeutic modality for prostate cancer
beyond its commonly described associations with cell
morphology and transformation.
In the present study, we made certain observations. (1)
Vav3 was overexpressed in LNCaP cells cultured under
chronic hypoxia (LNCaPH) characterizing androgen inde-
pendence [25]. (2) Vav3 activated pro-survival signaling
pathways, including the activation of PI3K/Akt and ERK,
which caused downstream Bad and AR phosphorylation
in LNCaPH cells. (3) Downregulation of Vav3 signaling
pathways by siRNA in combination with docetaxel signifi-
cantly inhibited LNCaPH cell growth through theinduction of apoptosis in vitro and in mouse xenografts
in vivo. (4) si-Vav3 inhibited the phosphorylation of Akt
and ERK, resulting in the inhibition of Bad and AR phos-
phorylation. (5) Docetaxel also inhibited the phosphoryl-
ation of Akt and ERK but activated JNK, resulting in
increased Bcl-2 phosphorylation, and decreased Bad phos-
phorylation. To the best of our knowledge, this is the first
report to show that siRNA knockdown of Vav3 can be
combined with docetaxel against prostate cancer to yield
increased sensitivity in vitro and in vivo.
Recent studies have suggested controversies in the
roles of hypoxic tumor microenvironment in prostate
cancer. Dihydrotestosterone increased hypoxia response
element (HRE)-mediated transcriptional activity in pros-
tate cancer, and androgen is involved in the response to
hypoxia through hypoxia-inducible factor-1α [29]. In
addition, castration therapy was reported to decrease the
synthesis of vascular growth factors, such as VEGF and
angiopoietins, and upregulate hypoxia, leading to apop-
tosis in prostate cancer [30]. Therefore, androgen
deprivation therapy, which induces apoptosis by degen-
erating the vascular support system of the tumor, is rea-
sonable for androgen-dependent prostate cancer. In
contrast, tumor hypoxia is progressively associated with
increased AR activity, reduced oxidative defense, gen-
omic instability, and apoptosis resistance, and it may be
associated with the transition to androgen independence
in prostate cancer [31,32]. Suzuki et al. reported that
prostate cancer progresses in hypoxic conditions and
transforms to the androgen independent state by suppress-
ing the androgen response [33]. Moreover, Butterworth
et al. also demonstrated that hypoxia could select for an-
drogen-independent prostate cancer cells with more malig-
nant behaviors including invasion and metastasis [34]. In
other words, hypoxia may select androgen-independent
prostate cancer with a more malignant phenotype. We also
previously reported that chronic hypoxia markedly potenti-
ated androgen-independent growth and malignant behavior
in LNCaP cells [25]. Hence, it appears important to over-
come the hypoxia-induced malignant potential reflecting
the androgen-independent state in prostate cancer.
Vav3 has been identified as a Ros receptor protein tyro-
sine kinase-interacting protein functioning as a signaling
molecule downstream of Ros [23]. Vav3 also plays a role
in epidermal growth factor receptor-, insulin receptor-,
and insulin-like growth factor-mediated signaling path-
ways [23]. Lyons et al. reported that Vav3 expression is el-
evated in prostate cancer specimens and is coupled to
growth factor receptor pathways that are upregulated dur-
ing the progression of androgen-dependent prostate can-
cer cells to the androgen-independent state [15]. Because
Vav3 expression in LNCaP cells was also increased after
long-term androgen deprivation, the possibility that Vav3
expression plays a role in the acquisition of androgen
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previous study revealed that androgen-dependent LNCaP
cells could acquire androgen independence through Vav3
overexpression when cultured under chronic hypoxia
[24,25]. That is, prostate cancer under chronic hypoxia
may reflect the androgen independent state with Vav3
overexpression.
We hypothesized that Vav3 may be a key therapeutic
target molecule in the regulation of prostate cancer
growth and survival under chronic hypoxia. To test this
hypothesis, we examined the effects of Vav3 depletion by
siRNA on cell growth and downstream cell signaling path-
ways in LNCaPH cells. We demonstrated that si-Vav3
alone inhibited LNCaPH cell growth and induced apop-
tosis in vitro and in mouse xenografts in vivo. These re-
sults are consistent with previous observations reported
by Dong et al., in which Vav3 depletion by siRNA
inhibited growth in both androgen-dependent and andro-
gen independent prostate cancer [17]. However, the effect
of si-Vav3 was weak and this study was designed to deter-
mine the combinatorial effects of docetaxel on cancer cell
growth and apoptosis. In this study, we noted that the
growth-inhibitory effect of si-Vav3 on LNCaPH cells
occurred through a decrease in phosphorylated Akt and
ERK, leading to the induction of apoptosis (Figures 2 and
3). Accompanying this apoptotic induction, we observed
that si-Vav3 could induce caspase-9 activation (Figure 3)
but not casapase-8 activation (data not shown). Taken to-
gether, these results suggest that si-Vav3-induced apop-
tosis mainly depends on mitochondrial pathways rather
than death receptor-mediated pathways. In addition, com-
bination treatment significantly decreased the phosphoryl-
ation of Akt and ERK and increased the phosphorylation
of JNK. This indicates that combined si-Vav3 and
docetaxel treatment increased apoptosis by modulating
Akt, ERK, and JNK phosphorylation.
si-Vav3 induced the apoptotic activity of the pro-apop-
totic member of the Bcl-2 family protein Bad, which is a
common target of Akt and ERK [35,36]. We noted that
inhibition of survival kinase cascades targeting Bad, in-
cluding the inhibition of Akt and ERK phosphorylation
by si-Vav3, resulted in apoptosis (Figures 2 and 3). In
addition, si-Vav3 simultaneously inhibited the androgen
signaling mediated by AR, a ligand-activated transcrip-
tion factor and survival factor. It has been amply docu-
mented that AR, PI3K/Akt, and ERK pathways are
important features contributing to uncontrolled prostate
cancer cell growth and survival. In addition, increased
AR activity is caused by crosstalk between AR and mul-
tiple intracellular signaling cascades, particularly PI3K/
Akt and ERK pathways [17,37]. Consistent with a previ-
ous report, Vav3 downregulation inhibited AR phosphor-
ylation through its convergent signaling network of
PI3K/Akt and ERK in LNCaPH cells. Because PI3K/Aktand ERK pathways can regulate prostate cancer survival
through the AR pathway, we investigated whether
inhibiting PI3K/Akt and ERK pathways by kinase-specific
inhibitors could affect AR phosphorylation. We found that
treatment with LY294002 or U0126 decreased the phos-
phorylation of AR with a concomitant reduction of Akt
and ERK phosphorylation in both LNCaP and LNCaPH
cells (Figure 4). Thus, treatment with LY294002 increased
apoptosis, whereas the effect of U0126 on cell apoptosis
was attenuated compared with that of LY294002 because
of the low level of basal ERK activity. Interestingly, the ef-
fects of LY294002 on apoptosis was stronger in LNCaPH
cells than in LNCaP cells because of the high basal Akt
phosphorylation level. Collectively, these results indicate
that the PI3K/Akt signaling pathway plays a crucial role in
LNCaPH cell growth, although cancer cell growth regu-
lated by Vav3, at least in part, originated from activated
ERK signaling. Our observations support the view that the
PI3K/Akt pathway, which is activated by Vav3, is mainly
involved in AR activity in prostate cancer development
and progression [17,38].
In this study, although docetaxel also induced LNCaPH
cell apoptosis by the inhibition of Bad phosphorylation in-
cluding the inhibition of Akt and ERK phosphorylation,
the level of AR phosphorylation was unaffected by
docetaxel. It has been reported that docetaxel can induce
apoptosis by PI3K/Akt inhibition in prostate cancer [39].
Similarly, our findings suggested that Bad phosphorylation
is mainly regulated by the PI3K/Akt pathway because
basal ERK activity is very low in LNCaPH cells, although
ERK phosphorylation is inhibited by docetaxel.
JNK, also called SAPK, is involved in development,
morphogenesis, cell differentiation, and cell death in re-
sponse to various environmental stresses including mito-
gen growth factors, inflammatory cytokines, oxidative
stress, and diverse extracellular stimuli including cyto-
toxic drugs. Depending on the stimulus and cell type,
JNK has essential roles in modulating the function of the
mitochondrial pro- and anti-apoptotic proteins, such as
Bcl-2 and Bad [40,41]. A previous study demonstrated
that the duration and intensity of JNK activation are associ-
ated with apoptotic cell death and that Bad dephosphoryla-
tion is accompanied by increases in JNK phosphorylation
and activity [42]. Moreover, JNK activation leads to inacti-
vation of the survival functions of Bcl-2 through Bcl-2
phosphorylation [43]. In this study, Bad dephosphorylation
and Bcl-2 phosphorylation with an elevation of JNK phos-
phorylation were induced by docetaxel, suggesting that
JNK positively regulates apoptosis induction through Bad
dephosphorylation and Bcl-2 phosphorylation.
Conclusions
In summary, this study demonstrated that Vav3-mediated
signaling converges with PI3K/Akt, ERK, and AR signaling
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cancer cells under chronic hypoxia. Because the pAR-
positive cell ratio was not found to be associated with
apoptosis and tumor growth delay in in vivo analysis,
LNCaPH cell growth appeared to be regulated by both
AR-dependent and AR-independent pathways. Therefore,
si-Vav3, which targets the PI3K/Akt, ERK, and AR signal-
ing axis, was effective when combined with docetaxel,
which targets Bcl-2 and Bad. Increased Bad and AR phos-
phorylation by the activation of PI3K/Akt and ERK signal-
ing pathways upon Vav3 stimulation contributes to
prostate cancer growth under chronic hypoxia (Figure 6A),
whereas increased Bcl-2 phosphorylation and decreased
Bad phosphorylation through the activation of JNK signal-
ing by docetaxel coupled with decreased phosphorylation
of Bad and AR through the inhibition of PI3K/Akt and
ERK signaling pathways upon the addition of si-Vav3 con-
tributes to increased apoptosis (Figure 6B). The present
study describes a potentially useful approach of utilizing
the combination of docetaxel and si-Vav3 to enhance
the apoptosis of prostate cancer cells under chronic













Figure 6 Proposed molecular mechanisms of Vav3-mediated signalin
expression under chronic hypoxia, Vav3 can phosphorylate Bad at Ser 112
cancer cell survival. B, Vav3 siRNA can inhibit Vav3-mediated signaling path
dephosphorylate Bad through JNK and PI3K/Akt pathways, respectively, and
caspase cascade, resulting in apoptosis.no toxicity in mice, which makes it an attractive and safe
therapeutic strategy in future clinical application to
treat prostate cancer. This approach may provide a
novel strategy for the treatment of HRPC, particularly
advanced prostate cancer in which the Vav3 signaling
pathway is activated.Methods
Cell culture and hypoxia induction
LNCaP human prostate cancer cells were maintained in
RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Bio-Whittaker,
Walkersville, MD, USA), 50 IU/ml penicillin, and 50 μg/ml
streptomycin (GibcoBRL, Grand Island, NY, USA) and cul-
tured at 37°C in a humidified atmosphere of 5% CO2. To
establish chronic hypoxia-conditioned LNCaP (LNCaPH)
cells, LNCaP cells were cultured under hypoxia (1% O2)
for 6 months. The experiments using LNCaPH cells were
performed under hypoxic conditions. KPK13 human renal
cell carcinoma cells were cultured in minimum essential












g pathways in LNCaPH cells. A, following the induction of Vav3
and AR at Ser 81 through PI3K/Akt and ERK pathways, resulting in
ways and docetaxel can phosphorylate Bcl-2 at Ser 70 and
thus, these two signaling pathways can merge to activate the
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CO2 at 37°C.
Immunocytochemistry
Cultured cells were washed with PBS, fixed in methanol
for 20 min, and incubated in 10% goat normal serum
(Nichirei, Tokyo, Japan) for 10 min at 37°C. Cells were in-
cubated in a primary antibody against Vav3 (1:50 dilution;
Epitomics, Burlingame, CA, USA) at room temperature in
PBS with 1% BSA for 60 min. After incubation with the
primary antibody, the secondary antibody fluorescein dye
(Alexa Fluor 488)-conjugated goat anti-rabbit IgG (1:40
dilution) (Invitrogen, Carlsbad, CA, USA) was added in
PBS with 1% BSA for 30 min. Cells were visualized using
confocal laser microscopy followed by nuclear staining with
1 μg/ml 2,4-diamidino-2-phenylindole dihydrochloride
n-hydrate (Dojindo, Kumamoto, Japan).
Transient transfection of Vav3 siRNA
Cells were transiently transfected with a Vav3 siRNA du-
plex (si-Vav3; final concentration of 60 nmol/l) or a control
siRNA (a random scrambled sequence: si-Scr; final concen-
tration of 60 nmol/l) using Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s instructions.
The sequence of the siRNA against Vav3 synthesized by
Invitrogen is 50- AUAUUCUCCUGACUCUUUGGUCC
UG(dT)(dT)-30. Following transfection, cells were sub-
jected to growth inhibition, live/death, flow cytometric,
and immunoblot analyses.
Growth inhibition assay
Cell viability was determined using a cell proliferation
assay. In brief, exponentially growing cells were seeded
in 6-well plates at 1 × 105 cells/well. After overnight cul-
ture, the culture medium was changed to fresh standard
medium containing 5 nM docetaxel (Sigma, St. Louis,
MO, USA) for 0–72 h or various concentrations of
docetaxel (0, 1, 2.5, and 5 nM) for 72 h in the presence
or absence of si-Vav3. After treatment, the cell number
was counted with a hemocytometer.
Live/death analysis
Cells were treated with si-Vav3, 5 nM docetaxel, or si-
Vav3 plus 5 nM docetaxel for 48 h. Live and dead cells
were detected using the Live/Death Viability/Cytotoxicity
assay kit (Molecular Probes, Eugene, OR) for which
fluorescence was observed and pictures were taken at
4× magnification. The data from three independent
experiments were expressed as a mean percentage.
Flow cytometric and DNA fragmentation analyses
For cell cycle analysis, flow cytometric analysis of
propidium iodide-stained nuclei was performed. In brief,
cells treated with si-Vav3, 5 nM docetaxel, or si-Vav3plus 5 nM docetaxel for 0–72 h or various concentra-
tions of docetaxel (0, 1, 2.5, and 5 nM) for 72 h in the
presence or absence of si-Vav3 were plated at a density
of 5 × 105 cells in a 60-mm dish overnight. The cells
were collected by trypsinization and fixed with 70% etha-
nol. The fixed cells were incubated with 100 μg/ml RNase
A (Sigma) for 30 min and stained with 25 μg/ml propidium
iodide (Chemicon, Temecula, CA, USA) for 30 min. Cell
cycle distribution was analyzed with a FACScan flow
cytometer and CellQuest software (Becton Dickinson
Labware, Lincoln Park, NJ, USA). The data from three in-
dependent experiments were expressed as a mean percent-
age. The apoptotic response was also measured by the Cell
Death Detection ELISAPLUS photometric enzyme immuno-
assay for the quantitative determination of cytoplasmic his-
tone-associated DNA fragments (Roche, Indianapolis, IN,
USA). In brief, the cytoplasmic fractions of the untreated
control cells and cells treated with si-Scr, si-Vav3, 5 nM
docetaxel, or si-Vav3 in combination with 5 nM docetaxel
were transferred to a streptavidin-coated plate and incu-
bated for 2 h at room temperature with a mixture of
peroxidase-conjugated anti-DNA and biotin-labeled
antihistone. The plate was washed thoroughly and incu-
bated with 2, 20-azino-di[3-ethylbenzthiazolin-sulfonate].
The absorbance was measured at 405 nm with a reference
wavelength of 492 nm.
Cytotoxicity assay
To determine the involvement of PI3K/Akt, ERK, and
c-jun N-terminal kinase (JNK) pathways in cell apoptosis,
cells were treated with LY294002 (Calbiochem, Darmstadt,
Germany), U0126 (Calbiochem), or SP600125 (Sigma), re-
spectively, for 48 h. Control cells were cultured in the
presence of an equivalent amount of DMSO as a vehicle.
Immunoblot analysis
Protein was extracted from cell pellets with a lysis buffer
(50 mM Tris, pH 8.0, 150 mM NaCl, 0.02% NaN3, 0.1%
SDS, 1% NP-40, 0.5% sodium deoxycholate, and 1 mM
PMSF) in the presence of a protease inhibitor cocktail
(Roche Applied Science, Indianapolis, IN, USA). Samples
containing equal amounts of protein (30 μg) were
electrophoresed on 8–16% Tris-glycine gels (Invitrogen)
and transferred to nitrocellulose membranes. After
blocking with T-TBS containing 5% nonfat milk powder,
the membranes were incubated with mouse monoclonal
antibody against phospho-Akt (Ser 473) (1:1000 dilution;
Cell Signaling, Danvers, MA, USA), phospho-ERK (Thr
202/Tyr 204) (1:1000 dilution; Cell Signaling), phospho-
stress−activated protein kinase (SAPK)/JNK (Thr 183/
Tyr 185) (1:1000 dilution; Cell Signaling), and Bcl-2
(1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), or rabbit polyclonal antibodies against Vav3
(1:1000 dilution; Cell Signaling), Akt (1:1000 dilution;
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technology), phospho-Bcl-2 (Ser 70) (1:1000 dilution;
Cell Signaling), Bad (1:1000 dilution; Cell Signaling),
phospho-Bad (Ser 136) (1:1000 dilution; Cell Signaling),
ERK (1:1000 dilution; Cell Signaling), SAPK/JNK (1:1000
dilution; Cell Signaling), AR (1:1000 dilution; Millipore,
Temecula, CA), phospho-AR (Ser 81) (1:500 dilution;
Millipore), caspase-3 (1:1000 dilution; Cell Signaling),
caspase-9 (1:500 dilution; Cell Signaling), or poly(ADP-
ribose) polymerase (PARP) (1:1000 dilution; Cell Signal-
ing) at 4°C overnight. After washing with T-TBS, the
membranes were incubated with corresponding second-
ary antibodies, which were conjugated with horseradish
peroxidase (Santa Cruz Biotechnology). The blots were
stripped and reprobed with anti-β-tubulin antibody
(1:5000 dilution; Sigma). Immunoreactive bands were vi-
sualized with ECL plus (Amersham Pharmacia Biotech,
Little Chalfont, UK) and quantified by scanning densi-
tometry using NIH Image software (version 1.55).
Formation of siRNA/atelocollagen complex
Atelocollagen is a type I collagen of calf dermis that is
highly purified by pepsin treatment (Koken Co., Ltd,
Tokyo, Japan). The siRNA and atelocollagen complexes
were prepared as follows. An equal volume of atelocollagen
(in PBS at pH 7.4) and siRNA solution was combined and
mixed by rotation at 4°C for 20 min. The final concentra-
tion of atelocollagen in vivo was 0.5%.
In vivo animal experiment
Four-week-old male athymic nude mice (20–24 g;
BALB/c nu/nu mice) were housed in accordance with
and approved by the Institutional Animal Care and Use
Committee of Oita University. For subcutaneous injec-
tion, LNCaPH cells were trypsinized, and single-cell sus-
pensions (2 × 106 cells) were mixed 1:1 with Matrigel
and then injected into both flanks. To determine the op-
timal concentration of the siRNA/atelocollagen complex,
dose–response tests including si-Scr as a vehicle control
and si-Vav3 were performed. Three weeks after the in-
jection of mice with LNCaPH cells, when the tumor vol-
ume reached 100 mm3, the mice were randomly divided
into seven treatment groups (non-treatment; 0.5 μg,
2.5 μg, and 10 μg of si-Scr/tumor; 0.5 μg, 2.5 μg, and
10 μg of si-Vav3/tumor), each consisting of four mice.
The siRNA/atelocollagen complex was injected directly
into the tumors once a week for 7 consecutive weeks.
Tumor size was quantified by measuring in two dimen-
sions with calipers, and tumor volume was calculated
every 7 days according to the equation (l × w2)/2, where
l = length and w = width. The mice were monitored
daily for changes in weight and other signs of acute tox-
icity. After optimizing the concentration of the siRNA/
atelocollagen complex (2.5 μg siRNA/50 μl/tumor), theeffects of combination therapy with docetaxel was
assessed. Tumor cell-bearing mice were randomly divided
into four treatment groups (si-Scr, si-Vav3, docetaxel, and
docetaxel + si-Vav3), each consisting of four mice. An
intratumoral injection of the siRNA/atelocollagen complex
(si-Vav3 or si-Scr) was performed with or without
docetaxel 10 mg/kg i.p. once weekly for 7 consecutive
weeks. When treatments were completed, animals were
sacrificed, and tumor tissues were harvested for immuno-
blot analysis, H&E staining and immunohistochemistry.
Immunohistochemical protocol
After sacrifice, s.c. tumor tissues were fixed with 10%
buffered formalin and embedded in paraffin. The forma-
lin-fixed, paraffin-embedded tissues were cut to 4-μm
sections and deparaffinized in xylene followed by treat-
ment with a graded series of ethanol and rehydration in
PBS. The sections were incubated in 0.3% H2O2 for 10 min
to inactivate endogenous peroxidase, followed by washing
in PBS. To block non-specific binding to sections and
eliminate non-specific staining, 10% normal goat serum in
PBS was applied and incubated for 10 min. The following
primary antibodies were used: Vav3, Ki-67 (DAKO,
Carpinteria, CA, USA), phospho-AR (pAR) (Abnova,
Thaipei, Taiwan), and M30 CytoDeath (Roche Applied Sci-
ence, Mannheim, Germany). They were diluted 50×, 1×,
100×, and 50×, respectively, with PBS containing 1% BSA.
After washing with PBS, sections were incubated with sec-
ondary antibodies, which were conjugated with peroxid-
ase-labeled amino acid polymer (DAKO). The immune
complex was visualized using a 3,30-diaminobenzidine
peroxytrichloride substrate solution (DAKO). Slides were
then counterstained with hematoxylin and mounted. The
evaluation of Ki-67, pAR, and M30 CytoDeath staining
was based on the proportion of positive-stained cells
among a total of 1000 cells that were counted in five ran-
domly selected areas.
Statistical analysis
Values were expressed as means ± SE. Statistical analysis
was performed using Student’s t-test. The limit for statis-
tical significance was set at P <0.05.
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